SCHEMBL4739508

SCHEMBL4739508

Cc1ccc(-c2ccc(NC(=O)Nc3cccc(F)c3)cc2)c2c(N)onc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.63
KIT P10721 14/20 0.63
FLT3 P36888 15/20 0.62
PDGFRB P09619 6/20 0.62
FLT1 P17948 6/20 0.55
CSF1R P07333 5/20 0.55
LCK P06239 4/20 0.55
FYN P06241 4/20 0.55
LYN P07948 4/20 0.55
FLT4 P35916 4/20 0.55
BLK P51451 4/20 0.55
SRC P12931 3/20 0.55
ABL1 P00519 2/20 0.55
AURKA O14965 3/20 0.54
ROCK2 O75116 3/20 0.54
RPS6KA5 O75582 3/20 0.54
MAP4K4 O95819 3/20 0.54
NTRK1 P04629 3/20 0.54
RET P07949 3/20 0.54
FGFR1 P11362 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739605 0.90 KDR (0.67) KDRKITFLT3PDGFRBFLT1
SCHEMBL4735873 0.89 KDR (0.64) KDRKITFLT3PDGFRBFLT1
SCHEMBL4787011 0.89 KDR (0.66) KDRKITFLT3PDGFRBFLT1
SCHEMBL1380780 0.88 FLT3 (0.58) KDRKITFLT3PDGFRBFLT1
SCHEMBL4735746 0.88 KDR (0.68) KDRKITFLT3PDGFRBFLT1
SCHEMBL1381417 0.88 KDR (0.66) KDRKITFLT3PDGFRBFLT1
SCHEMBL5249943 0.87 KDR (0.70) KDRKITFLT3PDGFRBFLT1
SCHEMBL5251843 0.86 KDR (0.58) KDRKITFLT3PDGFRBFLT1
SCHEMBL1385557 0.86 KDR (0.66) KDRKITFLT3PDGFRBFLT1
SCHEMBL421195 0.86 KDR (0.71) KDRKITFLT3PDGFRBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed